Williams CL, Porter RA, Phelps SH (1995) Inhibition of voltage-gated Ca²⁺ channel activity in

small cell lung carcinoma by the Ca²⁺/calmodulin-dependent protein kinase inhibitor KN-62

(1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperaz

ine).

Biochem

Pharmacol 50:1979–1985. https://doi.org/10.1016/0006-2952(95)02096-9

Williams CL, Phelps SH, Porter RA (1996) Expression of Ca²⁺/calmodulin-dependent protein

kinase types II and IV, and reduced DNA synthesis due to the Ca²⁺/calmodulin-dependent

protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-

phenyl piperazine) in small cell lung carcinoma. Biochem Pharmacol 51:707–715. https://doi.

org/10.1016/s0006-2952(95)02393-3

Yamada D et al (2013) Reduction of prostate cancer incidence by naftopidil, an alpha1-

adrenoceptor antagonist and transforming growth factor-beta signaling inhibitor. Int J Urol

20:1220–1227. https://doi.org/10.1111/iju.12156

Yokoyama T, Kumon H, Nasu Y, Takamoto H, Watanabe T (2006) Comparison of 25 and

75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyper-

plasia: a prospective, randomized controlled study. Int J Urol 13:932–938. https://doi.org/10.

1111/j.1442-2042.2006.01443.x

120

K. Ishii et al.